|
2018 Conference Publication CA224-047: A randomized, double-blind, phase II/III study of relatlimab (anti-LAG-3) in combination with nivolumab (anti-PD-1) versus nivolumab alone in previously untreated metastatic or unresectable melanomaLipson, E. J., Long, G. V., Tawbi, H., Schadendorf, D., Atkinson, V. G., Maurer, M., Simonsen, K. L., Harbison, C. and Hodi, F. S. (2018). CA224-047: A randomized, double-blind, phase II/III study of relatlimab (anti-LAG-3) in combination with nivolumab (anti-PD-1) versus nivolumab alone in previously untreated metastatic or unresectable melanoma. 43rd ESMO Congress (ESMO 2018), Munich, Germany, 19–23 October 2018. Amsterdam, Netherlands: Elsevier. doi: 10.1093/annonc/mdy289.058 |
|
2018 Conference Publication Adverse events (AEs) over time in patients (pts) treated with adjuvant dabrafenib plus trametinib (D + T) or placebo (Pbo) in the COMBI-AD trialAtkinson, V. G., Hauschild, A., Santinami, M., Mandala, M., Chiarion Sileni, V., Larkin, J., Nyakas, M. S., Dutriaux, C., Haydon, A., Mortier, L., Robert, C., Schachter, J., Schadendorf, D., Feng, X., de Jong, E., Mookerjee, B., Kefford, R., Dummer, R., Kirkwood, J. M. and Long, G. V. (2018). Adverse events (AEs) over time in patients (pts) treated with adjuvant dabrafenib plus trametinib (D + T) or placebo (Pbo) in the COMBI-AD trial. 43rd ESMO Congress (ESMO 2018), Munich, Germany, 19–23 October 2018. Amsterdam, Netherlands: Elsevier. doi: 10.1093/annonc/mdy289.007 |
|
2018 Journal Article Omitting radiosurgery in melanoma brain metastases: a drastic and dangerous de-escalationLong, Georgina V., Atkinson, Victoria, Hong, Angela, McArthur, Grant A. and Menzies, Alexander M. (2018). Omitting radiosurgery in melanoma brain metastases: a drastic and dangerous de-escalation. Lancet Oncology, 19 (8), E367-E367. doi: 10.1016/S1470-2045(18)30508-4 |
|
2018 Journal Article The changing paradigm of management in melanoma brain metastasesLadwa, Rahul and Atkinson, Victoria (2018). The changing paradigm of management in melanoma brain metastases. Asia Pacific Journal of Clinical Oncology, 14 (6), 453-458. doi: 10.1111/ajco.12998 |
|
2018 Journal Article Neoadjuvant chemotherapy or chemoradiotherapy for adenocarcinoma of the esophagusVisser, Els, Edholm, David, Smithers, B. Mark, Thomson, Iain G., Burmeister, Bryan H., Walpole, Euan T., Gotley, David C., Joubert, Warren L., Atkinson, Victoria, Mai, Tao, Thomas, Janine M. and Barbour, Andrew P. (2018). Neoadjuvant chemotherapy or chemoradiotherapy for adenocarcinoma of the esophagus. Journal of Surgical Oncology, 117 (8), 1687-1696. doi: 10.1002/jso.25089 |
|
2018 Journal Article Adjuvant pembrolizumab versus placebo in resected stage III melanomaEggermont, Alexander M. M., Blank, Christian U., Mandala, Mario, Long, Georgina V., Atkinson, Victoria, Dalle, Stéphane, Haydon, Andrew, Lichinitser, Mikhail, Khattak, Adnan, Carlino, Matteo S., Sandhu, Shahneen, Larkin, James, Puig, Susana, Ascierto, Paolo A., Rutkowski, Piotr, Schadendorf, Dirk, Koornstra, Rutger, Hernandez-Aya, Leonel, Maio, Michele, van den Eertwegh, Alfonsus J. M., Grob, Jean-Jacques, Gutzmer, Ralf, Jamal, Rahima, Lorigan, Paul, Ibrahim, Nageatte, Marreaud, Sandrine, van Akkooi, Alexander C. J., Suciu, Stefan and Robert, Caroline (2018). Adjuvant pembrolizumab versus placebo in resected stage III melanoma. The New England Journal of Medicine, 378 (19), 1789-1801. doi: 10.1056/NEJMoa1802357 |
|
2018 Journal Article Focal regression of a primary melanoma, fading lentigines, and poliosis in metastatic melanoma treated with anti-PD-1Thomas, S, Laino, A, Sturm, R, Nufer, K, Lambie, D, Shepherd, B, Atkinson, V, Adams, L, Soyer, H P and Schaider, H (2018). Focal regression of a primary melanoma, fading lentigines, and poliosis in metastatic melanoma treated with anti-PD-1. Journal of the European Academy of Dermatology and Venereology : JEADV, 32 (5), e176-e177. doi: 10.1111/jdv.14678 |
|
2018 Journal Article Combination nivolumab and ipilimumab or nivolumab alone in melanoma brain metastases: a multicentre randomised phase 2 studyLong, Georgina V., Atkinson, Victoria, Lo, Serigne, Sandhu, Shahneen, Guminski, Alexander D., Brown, Michael P., Wilmott, James S., Edwards, Jarem, Gonzalez, Maria, Scolyer, Richard A., Menzies, Alexander M. and McArthur, Grant A. (2018). Combination nivolumab and ipilimumab or nivolumab alone in melanoma brain metastases: a multicentre randomised phase 2 study. The Lancet Oncology, 19 (5), 672-681. doi: 10.1016/S1470-2045(18)30139-6 |
|
2018 Journal Article Acetylsalicylic acid governs the effect of sorafenib in RAS- mutant cancersHammerlindl, Heinz, Ravindran Menon, Dinoop, Hammerlindl, Sabrina, Emran, Abdullah Al, Torrano, Joachim, Sproesser, Katrin, Thakkar, Divya, Xiao, Min, Atkinson, Victoria G., Gabrielli, Brian, Haass, Nikolas K., Herlyn, Meenhard, Krepler, Clemens and Schaider, Helmut (2018). Acetylsalicylic acid governs the effect of sorafenib in RAS- mutant cancers. Clinical Cancer Research, 24 (5), 1090-1102. doi: 10.1158/1078-0432.CCR-16-2118 |
|
2018 Journal Article Survival Outcomes in Patients with Previously Untreated BRAF Wild-Type Advanced Melanoma Treated with Nivolumab Therapy: Three-Year Follow-up of a Randomized Phase 3 TrialAscierto, Paolo A., Long, Georgina V., Robert, Caroline, Brady, Benjamin, Dutriaux, Caroline, Di Giacomo, Anna Maria, Mortier, Laurent, Hassel, Jessica C., Rutkowski, Piotr, McNeil, Catriona, Kalinka-Warzocha, Ewa, Savage, Kerry J., Hernberg, Micaela M., Lebbé, Celeste, Charles, Julie, Mihalcioiu, Catalin, Chiarion-Sileni, Vanna, Mauch, Cornelia, Cognetti, Francesco, Ny, Lars, Arance, Ana, Svane, Inge Marie, Schadendorf, Dirk, Gogas, Helen, Saci, Abdel, Jiang, Joel, Rizzo, Jasmine and Atkinson, Victoria (2018). Survival Outcomes in Patients with Previously Untreated BRAF Wild-Type Advanced Melanoma Treated with Nivolumab Therapy: Three-Year Follow-up of a Randomized Phase 3 Trial. JAMA Oncology, 5 (2), 187-194. doi: 10.1001/jamaoncol.2018.4514 |
|
2017 Journal Article Pooled analysis safety profile of nivolumab and ipilimumab combination therapy in patients with advanced melanomaSznol, Mario, Ferrucci, Pier Francesco, Hogg, David, Atkins, Michael B., Wolter, Pascal, Guidoboni, Massimo, Lebbé, Celeste, Kirkwood, John M., Schachter, Jacob, Daniels, Gregory A., Hassel, Jessica, Cebon, Jonathan, Gerritsen, Winald, Atkinson, Victoria, Thomas, Luc, McCaffrey, John, Power, Derek, Walker, Dana, Bhore, Rafia, Jiang, Joel, Hodi, F. Stephen and Wolchok, Jedd D. (2017). Pooled analysis safety profile of nivolumab and ipilimumab combination therapy in patients with advanced melanoma. Journal of Clinical Oncology, 35 (34), 3815-3822. doi: 10.1200/JCO.2016.72.1167 |
|
2017 Journal Article Adjuvant dabrafenib plus trametinib in stage III BRAF-mutated melanomaLong, G. V., Hauschild, A., Santinami, M., Atkinson, V., Mandal, M., Chiarion-Sileni, V., Larkin, J., Nyakas, M., Dutriaux, C., Haydon, A., Robert, C., Mortier, L., Schachter, J., Schadendorf, D., Lesimple, T., Plummer, R., Ji, R., Zhang, P., Mookerjee, B., Legos, J., Kefford, R., Dummer, R. and Kirkwood, J. M. (2017). Adjuvant dabrafenib plus trametinib in stage III BRAF-mutated melanoma. New England Journal of Medicine, 377 (19), 1813-1823. doi: 10.1056/NEJMoa1708539 |
|
2017 Journal Article Adjuvant nivolumab versus ipilimumab in resected stage III or IV melanomaWeber, Jeffrey, Mandala, Mario, Del Vecchio, Michele, Gogas, Helen J., Arance, Ana M., Cowey, C. Lance, Dalle, Stéphane, Schenker, Michael, Chiarion-Sileni, Vanna, Marquez-Rodas, Ivan, Grob, Jean-Jacques, Butler, Marcus O., Middleton, Mark R., Maio, Michele, Atkinson, Victoria, Queirolo, Paola, Gonzalez, Rene, Kudchadkar, Ragini R., Smylie, Michael, Meyer, Nicolas, Mortier, Laurent, Atkins, Michael B., Long, Georgina V., Bhatia, Shailender, Lebbé, Celeste, Rutkowski, Piotr, Yokota, Kenji, Yamazaki, Naoya, Kim, Tae M. ... Ascierto, Paolo A. (2017). Adjuvant nivolumab versus ipilimumab in resected stage III or IV melanoma. New England Journal of Medicine, 377 (19), 1824-1835. doi: 10.1056/NEJMoa1709030 |
|
2017 Journal Article Nivolumab for Patients With Advanced Melanoma Treated Beyond Progression: Analysis of 2 Phase 3 Clinical TrialsLong, Georgina V., Weber, Jeffrey S., Larkin, James, Atkinson, Victoria, Grob, Jean-Jacques, Schadendorf, Dirk, Dummer, Reinhard, Robert, Caroline, Márquez-Rodas, Ivan, McNeil, Catriona, Schmidt, Henrik, Briscoe, Karen, Baurain, Jean-François, Hodi, F Stephen and Wolchok, Jedd D. (2017). Nivolumab for Patients With Advanced Melanoma Treated Beyond Progression: Analysis of 2 Phase 3 Clinical Trials. JAMA Oncology, 3 (11), 1511-1519. doi: 10.1001/jamaoncol.2017.1588 |
|
2017 Journal Article Recent advances in malignant melanomaAtkinson, Victoria (2017). Recent advances in malignant melanoma. Internal Medicine Journal, 47 (10), 1114-1121. doi: 10.1111/imj.13574 |
|
2017 Journal Article Standard-dose pembrolizumab in combination with reduced-dose ipilimumab for patients with advanced melanoma (KEYNOTE-029): an open-label, phase 1b trialLong, Georgine V., Atkinson, Victoria, Cebon, Jonathan S., Jameson, Michael B., Fitzharris, Bernie M., McNeil, Catriona M., Hill, Andrew G., Ribas, Antoni, Atkins, Michael B., Thompson, John A., Hwu, Wen-Jen, Hodi, F. Stephen, Menzies, Alexander M., Guminski, Alexander D., Kefford, Richard, Kong, Benjamin Y., Tamjid, Babak, Srivastava, Archana, Lomax, Anna J., Islam, Mohammed, Shu, Xinxin, Ebbinghaus, Scot, Ibrahim, Nageatte and Carlino, Matteo S. (2017). Standard-dose pembrolizumab in combination with reduced-dose ipilimumab for patients with advanced melanoma (KEYNOTE-029): an open-label, phase 1b trial. The Lancet Oncology, 18 (9), 1202-1210. doi: 10.1016/S1470-2045(17)30428-X |
|
2017 Conference Publication Adjuvant therapy with nivolumab (NIVO) versus ipilimumab (IPI) after complete resection of stage III/IV melanoma: A randomized, double-blind, phase 3 trial (CheckMate 238)Weber, J., Mandala, M., Del Vecchio, M., Gogas, H., Arance, A. M., Cowey, L. C., Dalle, S., Schenker, M., Chiarion-Sileni, V., Marquez-Rodas, I., Grob, J-J., Butler, M., Middleton, M. R., Maio, M., Atkinson, V., Queirolo, P., de Pril, V., Qureshi, A., Larkin, J. and Ascierto, P. A. (2017). Adjuvant therapy with nivolumab (NIVO) versus ipilimumab (IPI) after complete resection of stage III/IV melanoma: A randomized, double-blind, phase 3 trial (CheckMate 238). 42nd European-Society-for-Medical-Oncology Congress (ESMO), Madrid Spain, Sep 08-12, 2017. OXFORD: OXFORD UNIV PRESS. |
|
2017 Conference Publication A randomized, double-blind, placebo-controlled, phase III study comparing the combination of PDR001, dabrafenib and trametinib versus placebo, dabrafenib and trametinib in previously untreated patients with unresectable or metastatic BRAF V600-mutant melanoma (COMBI-i)Gasal, E., Arance Fernandez, A. M., Ascierto, P. A., Atkinson, V., Dummer, R., Flaherty, K. T., Grob, J-J., Hansson, J., Hassel, J., Larkin, J., Lebbe, C., Long, G. V., Lorigan, P., Miller, W., Nathan, P., Ribas, A., Robert, C., Schadendorf, D., Tawbi, H. and Upalawanna, A. (2017). A randomized, double-blind, placebo-controlled, phase III study comparing the combination of PDR001, dabrafenib and trametinib versus placebo, dabrafenib and trametinib in previously untreated patients with unresectable or metastatic BRAF V600-mutant melanoma (COMBI-i). 42nd European-Society-for-Medical-Oncology Congress (ESMO), Madrid Spain, Sep 08-12, 2017. OXFORD: OXFORD UNIV PRESS. |
|
2017 Conference Publication Immunotherapy in patients with concurrent solid organ transplant, HIV, and Hepatitis B and CRai, R., Ezeoke, O. M., McQuade, J. L., Zimmer, L., Koo, C., Park, J. J., Ardolino, L., Yip, D., Goldinger, S., Cohen, J. V., Millward, M., Atkinson, V., Kane, A. Y., Ascierto, P. A., Garbe, C., Gutzmer, R., Johnson, D. B., Hellman, M. D., Long, G. V. and Menzies, A. M. (2017). Immunotherapy in patients with concurrent solid organ transplant, HIV, and Hepatitis B and C. 42nd European-Society-for-Medical-Oncology Congress (ESMO), Madrid Spain, Sep 08-12, 2017. OXFORD: OXFORD UNIV PRESS. |
|
2017 Conference Publication COMBI-AD: Adjuvant dabrafenib (D) plus trametinib (T) for resected stage III BRAF V600E/K-mutant melanomaHauschild, A., Santinami, M., Long, G. V., Atkinson, V., Mandala, M., Sileni, V. Chiarion, Nyakas, M. S., Dutriaux, C., Haydon, A., Robert, C., Mortier, L., Schachter, J., Ji, R., Zhang, P., Mookerjee, B., Legos, J., Kefford, R., Dummer, R. and Kirkwood, J. (2017). COMBI-AD: Adjuvant dabrafenib (D) plus trametinib (T) for resected stage III BRAF V600E/K-mutant melanoma. 42nd European-Society-for-Medical-Oncology Congress (ESMO), Madrid Spain, Sep 08-12, 2017. OXFORD: OXFORD UNIV PRESS. |
